Mangold uppdaterar sin syn på medicinteknik-bolaget Miris.
Biovica records SEK 2.6m in total net sales (51% above Q1 last year), and clinical sales increased b...
Redeye initiates coverage of Guard Therapeutics, a clinical-stage biotech developing innovative ther...
Redeye comments on OncoZenge’s announcement of appointing LINK Medical as CRO for its pivotal phase ...
Redeye endorses the updated clinical guidelines in Japan supporting quantitative neuromuscular patie...
Redeye return with a research update following BioArctic's Q2 and latest newsflow.
Redeye provides an update following Litium’s acquisition of Geins, a small but strategically sound d...
With additional funds and a streamlined organisation, Sprint Bioscience continues to proactively pro...
Redeye views Hunter Capital's purchase of shares and warrants from Heights Capital Management as ope...
This adds to the initial evaluation announced by Q-linea’s regional partner earlier this year.
Vi inleder bevakning på Acenta Group, en internationell helhetsleverantör inom padelbranschen.
We are initiating coverage of Acenta Group, an international full-service provider within the padel ...
Acconeer has announced its A121 pulsed coherent radar has been selected by an additional Japanese ca...
Cell Impact står fortsatt inför stora utmaningar. Q2-rapporten för 2025 visar en omsättning på 2,1 M...
Redeye comments on Alzinova’s announcement that the FDA has approved its IND application for ALZ-101...
Botnia Gold redovisade ett starkt andra kvartal med intäkter på 115 Mkr och ett rörelseresultat på 4...
Redeye initiates coverage of Senzime, a Swedish medtech company specialising in quantitative neuromu...
mResell redovisade totala intäkter om 26,5 MSEK, varav nettoomsättningen uppgick till 25,5 MSEK, akt...
Ascelia has now submitted Orviglance to the FDA. The next step is to start the initial filing review...
Flexion is strengthening its position in the alternative app store market, securing four of the ten ...